All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub is pleased to present a visual abstract representing key data from the phase II HOVON146ALL trial (NCT03541083), evaluating blinatumomab added to prephase and consolidation therapy in newly diagnosed patients with ALL.
To download this visual abstract, click below.Download here
Does adding blinatumomab to frontline therapy improve survival outcomes for adults with B-ALL?
During the EHA 2022 Congress, the ALL Hub was pleased to speak to Anita Rijneveld, Erasmus MC, Rotterdam, NL. We asked, Does adding blinatumomab to...
How should we best sequence the new targeted therapies in relapsed B-ALL?
During the 8th Annual Meeting of the Society of Hematologic Oncology (SOHO), the ALL Hub spoke to Emily Curran, University of Cincinnati, Cincinnati, US. We asked, How should...
Subscribe to get the best content related to ALL delivered to your inbox